Dexcom [DXCM] vs Edwards Lifesciences [EW] Detailed Stock Comparison

Dexcom Inc.

NASDAQ
Loading...

Edwards Lifesciences Corporation

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Dexcom Inc. wins in 10 metrics, Edwards Lifesciences Corporation wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.

View Metrics Details

Vital Metrics Comparison

Metric Dexcom Inc. Edwards Lifesciences Corporation Better
P/E Ratio (TTM) 30.03 46.49 Dexcom Inc.
Price-to-Book Ratio 8.63 4.73 Edwards Lifesciences Corporation
Debt-to-Equity Ratio 50.85 6.82 Edwards Lifesciences Corporation
PEG Ratio 0.39 -0.62 Dexcom Inc.
EV/EBITDA 19.85 23.85 Dexcom Inc.
Profit Margin (TTM) 17.94% 17.39% Dexcom Inc.
Operating Margin (TTM) 25.64% 31.22% Edwards Lifesciences Corporation
EBITDA Margin (TTM) 25.64% 31.22% Edwards Lifesciences Corporation
Return on Equity 34.50% 10.38% Dexcom Inc.
Return on Assets (TTM) 8.89% 7.84% Dexcom Inc.
Free Cash Flow (TTM) $1.08B $1.34B Edwards Lifesciences Corporation
1-Year Return -8.07% 13.25% Edwards Lifesciences Corporation
Price-to-Sales Ratio (TTM) 5.10 7.70 Dexcom Inc.
Enterprise Value $23.09B $45.35B Edwards Lifesciences Corporation
EV/Revenue Ratio 4.95 7.20 Dexcom Inc.
Gross Profit Margin (TTM) 62.93% 78.15% Edwards Lifesciences Corporation
Revenue per Share (TTM) $12 $11 Dexcom Inc.
Earnings per Share (Diluted) $2.05 $1.81 Dexcom Inc.
Beta (Stock Volatility) 1.56 0.95 Edwards Lifesciences Corporation
Short % of Float 4.93% 1.84% Edwards Lifesciences Corporation

Dexcom Inc. vs Edwards Lifesciences Corporation Stock Performance Analysis

Loading Price Chart...

DXCM
EW

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Dexcom Inc.-1.53%-3.13%20.43%11.88%12.92%11.54%
Edwards Lifesciences Corporation1.37%0.50%6.02%3.26%3.48%1.11%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Dexcom Inc.-8.07%-42.07%-27.92%315.26%2,149.85%2,129.88%
Edwards Lifesciences Corporation13.25%-7.43%-15.49%159.09%507.93%2,151.59%

Performance & Financial Health Analysis: Dexcom Inc. vs Edwards Lifesciences Corporation

MetricDXCMEW
Market Information
Market Cap i$23.76B$48.52B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i4,652,6046,242,650
90 Day Avg. Volume i4,100,8485,032,270
Last Close$74.22$86.28
52 Week Range$54.11 - $89.98$72.30 - $89.48
% from 52W High-17.52%-3.58%
All-Time High$164.86 (Nov 15, 2021)$131.73 (Dec 27, 2021)
% from All-Time High-54.98%-34.50%
Growth Metrics
Quarterly Revenue Growth0.13%0.17%
Quarterly Earnings Growth0.76%0.06%
Financial Health
Profit Margin (TTM) i0.18%0.17%
Operating Margin (TTM) i0.26%0.31%
Return on Equity (TTM) i0.35%0.10%
Debt to Equity (MRQ) i50.856.82
Cash & Liquidity
Book Value per Share (MRQ)$7.14$17.80
Cash per Share (MRQ)$5.19$7.28
Operating Cash Flow (TTM) i$1.44B$1.50B
Levered Free Cash Flow (TTM) i$719.54M$1.07B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Dexcom Inc. vs Edwards Lifesciences Corporation

MetricDXCM (Apr 26, 2026)EW (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i30.0346.49
Forward P/E i20.5925.05
PEG Ratio i0.39-0.62
Price to Sales (TTM) i5.107.70
Price to Book (MRQ) i8.634.73
Market Capitalization
Market Capitalization i$23.76B$48.52B
Enterprise Value i$23.09B$45.35B
Enterprise Value Metrics
Enterprise to Revenue i4.957.20
Enterprise to EBITDA i19.8523.85
Risk & Other Metrics
Beta i1.560.95
Book Value per Share (MRQ) i$7.14$17.80

Financial Statements Comparison: Dexcom Inc. vs Edwards Lifesciences Corporation

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricDXCM (2025)EW (2025)
Revenue/Sales i4.66B6.07B
Cost of Goods Sold i1.86B1.33B
COGS % of Revenue i39.9%22.0%
Gross Profit i2.80B4.73B
Gross Margin i60.1%78.0%
Research & Development i599.10M1.08B
Operating Income (EBIT) i911.80M1.64B
Operating Margin i19.6%27.0%
EBITDA i1.36B1.96B
EBITDA Margin i29.1%32.4%
Pre-Tax Income i1.09B1.27B
Pre-Tax Income % of Revenue i23.3%21.0%
Income Tax i252.10M216.90M
Income Tax % of Revenue i5.4%3.6%
Net Income (Profit) i836.30M1.07B
Profit Margin i17.9%17.6%

Balance Sheet & Liquidity Metrics

MetricDXCM (2025)EW (2025)
Cash & Equivalents i917.70M2.94B
Total Current Assets i4.03B6.74B
Total Current Assets % of Revenue i86.5%111.1%
Total Current Liabilities i2.14B1.81B
Total Current Liabilities % of Revenue i46.0%29.9%
Long-Term Debt i1.37B680.90M
Long-Term Debt % of Revenue i29.3%11.2%
Total Shareholders Equity i2.75B10.34B
Retained Earnings i2.43B14.24B
Retained Earnings % of Revenue i52.2%234.7%
Property, Plant & Equipment i77.40M102.70M

Cash Flow Statement Comparison

MetricDXCM (2025)EW (2025)
Operating Cash Flow i1.48B1.50B
Operating Cash Flow % of Revenue i31.7%24.7%
Capital Expenditures i-363.50MN/A
Free Cash Flow i1.08B1.34B
FCF Margin i23.1%22.0%
Debt Repayment i-1.21BN/A
Common Stock Repurchase i-500.00M-893.40M

Short Interest & Institutional Ownership Analysis

MetricDXCMEW
Shares Short i14.72M9.33M
Short Ratio i3.772.05
Short % of Float i4.93%1.84%
Shares Outstanding i384.80M580.70M
Float Shares i382.94M579.02M
% Held by Insiders i0.28%0.17%
% Held by Institutions i101.50%92.88%
% Held by Public i-1.78%6.95%

Dividend Analysis & Yield Comparison: Dexcom Inc. vs Edwards Lifesciences Corporation

MetricDXCMEW
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A